Who are Code Biotherapeutics's investors?

Code Biotherapeutics's investors include New Enterprise Associates (NEA), Hatteras Venture Partners.

How much funding has Code Biotherapeutics raised?

Code Biotherapeutics has disclosed $47.5M raised across 2 rounds.

Where is Code Biotherapeutics headquartered?

Code Biotherapeutics is headquartered in Hatfield, US.

Code Biotherapeutics

Hatfield, US · Founded 2020 · 24 employees on LinkedIn · 2 known investors

Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.

Biotech Deep Tech Healthtech

Founders & leadership

Lauren KaskielExecutive

Robert C. GettsNamed on SEC filing

Brian McVeighNamed on SEC filing

Board

Dmitry KuzminBoard director

Victor StoneBoard director

Edward MathersBoard director

Robert LinBoard director

Russ FeinBoard director

Joseph TruittBoard director

Kathy RouanBoard director

Investors · 2

New Enterprise Associates (NEA)Menlo Park · $200K – $40M

Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M

Reported raises · per SEC filings

Form D private placements

$47.5M disclosed across 2 rounds · 2021–2022

▶$37.5MraisedJun 2022 · 10 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Joseph TruittDirector
Victor StoneDirector
Brian McVeighExecutive Officer, Director
Edward MathersDirector
Kathy RouanDirector
Robert C GettsExecutive Officer
Robert LinDirector
Dmitry KuzminDirector
Russ FeinExecutive Officer, Director
Lauren KaskielExecutive Officer
Erin BrubakerExecutive Officer

Offering amount: $75M
Amount sold: $37.5M
First sale: May 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedApr 2021 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Dmitry KuzminDirector
Victor StoneDirector
Lauren KaskielExecutive Officer
Robert C. GettsExecutive Officer
Joseph TruittDirector
Edward MathersDirector
Brian McVeighExecutive Officer, Director
Kathy RouanDirector
Robert LinDirector
Russ FeinDirector

Offering amount: $10M
Amount sold: $10M
First sale: Mar 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Code Biotherapeutics do?: Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.
Who are Code Biotherapeutics's investors?: Code Biotherapeutics's investors include New Enterprise Associates (NEA), Hatteras Venture Partners.
How much funding has Code Biotherapeutics raised?: Code Biotherapeutics has disclosed $47.5M raised across 2 rounds.
Where is Code Biotherapeutics headquartered?: Code Biotherapeutics is headquartered in Hatfield, US.